Rev Esp Quimioter 2022; 35(3): 284-287
Evaluation of a lateral flow immunoassay to detect CTX-M extended-spectrum β-lactamases (ESBL) directly from positive blood cultures for its potential use in Antimicrobial Stewardship programs
EMILIO CENDEJAS-BUENO, MARÍA DEL PILAR ROMERO-GÓMEZ, IKER FALCES-ROMERO, ALFONSO ARANDA-DIAZ, DIANA GARCÍA-BALLESTEROS, JESÚS MINGORANCE, JULIO GARCÍA-RODRÍGUEZ
Published: 31 March 2022
Background. Bloodstream infections (BSI) caused by extended-spectrum beta-lactamases Enterobacteriaceae (ESBL-E) are associated with high rates of treatment failure and increased mortality, especially when appropriate antimicrobial therapy is delayed. Our aim was to evaluate the anticipation of ESBLs detection and the potential improvement of the time response of the Vitek 2 System (BioMérieux; France).
Methods. We compared this lateral flow immunoassay when used directly on fluid from positive blood cultures to the VITEK2 AST system. We evaluated 80 isolates, 61 tested directly on fluid from positive blood cultures and 19 tested on fluid from blood cultures spiked with known ESBL positive and negative organisms.
Results. The concordance between the CTX-LFIA and the reference method (Vitek 2) had a Cohen´s Kappa coefficient of 0.97, indicating a particularly good correlation between both compared methods.
Conclusion. This lateral flow immunoassay can be more rapid than the Vitek 2 for earlier presumptive identification of CTX- M ESBLs and can be useful to anticipate results and the adjustment of antimicrobial therapy.
Rev Esp Quimioter 2022; 35(3): 284-287 [Full-text PDF]